<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-931
Date of Submission: 2025-03-21

This report was submitted by a Nurse from Jordan-James Medical Center concerning patient ANON-PX-1076. The subject is an adult other with a significant medical history including type 2 diabetes, osteoarthritis, migraines, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intravenous route at a dosage of 95mg, initiated on 2025-01-10 for Gastroesophageal reflux disease and discontinued on 2025-02-03.

On approximately 2025-01-28, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Headache. The Dizziness was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Edge development rule may. Short structure record for lawyer fear. Team country will rather.</data>
report_id: ADR-2025-931
report_date: '2025-03-21'
patient_details:
  patient_id: ANON-PX-1076
  gender: Other
  relevant_history:
  - type 2 diabetes
  - osteoarthritis
  - migraines
  - seasonal allergies
suspected_drugs:
- drug_name: Omeprazole
  dosage: 95mg
  route_of_administration: Intravenous
  start_date: '2025-01-10'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
  end_date: '2025-02-03'
adverse_reactions:
- symptom_name: Dizziness
  onset_date: '2025-01-28'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
- symptom_name: Headache
  onset_date: '2025-01-28'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Highly Probable
  dechallenge_rechallenge: Positive rechallenge
  naranjo_score: 9
reporting_facility: Jordan-James Medical Center
reporter_type: Nurse
notes: Edge development rule may. Short structure record for lawyer fear. Team country
  will rather.
